{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:46:59Z","timestamp":1792007219548,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T00:00:00Z","timestamp":1276214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s10067-010-1513-4","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T21:57:03Z","timestamp":1276207023000},"page":"999-1005","source":"Crossref","is-referenced-by-count":10,"title":["Acrylamine-induced autoimmune phenomena"],"prefix":"10.1007","volume":"29","author":[{"given":"Bruce","family":"Rothschild","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,11]]},"reference":[{"key":"1513_CR1","first-page":"439","volume":"37","author":"JW Boltzer","year":"1983","unstructured":"Boltzer JW (1983) Systemic lupus erythematosus. I. Historical aspects. Maryland State Med J 37:439","journal-title":"Maryland State Med J"},{"key":"1513_CR2","first-page":"1","volume-title":"Systemic lupus erythematosus","author":"RG Lahita","year":"1987","unstructured":"Lahita RG (1987) Introduction. In: Lahita RG (ed) Systemic lupus erythematosus. Wiley, New York, pp 1\u20133"},{"key":"1513_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-857X(21)00942-X","volume":"14","author":"CD Smith","year":"1988","unstructured":"Smith CD, Cyr M (1988) The history of lupus erythematosus from Hippocrates to Osler. Rheumat Dis Clin N Amer 14:1","journal-title":"Rheumat Dis Clin N Amer"},{"key":"1513_CR4","first-page":"3","volume-title":"Lupus erythematosus","author":"JH Talbott","year":"1987","unstructured":"Talbott JH (1987) Historical background of discoid and systemic lupus erythematosus. In: Wallace DL, Dubois EL (eds) Lupus erythematosus. Lea & Febiger, Philadelphia, pp 3\u201311"},{"key":"1513_CR5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archderm.1945.01510210032007","volume":"51","author":"BJ Hoffman","year":"1945","unstructured":"Hoffman BJ (1945) Sensitivity of sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph 51:190\u2013192","journal-title":"Arch Dermatol Syph"},{"key":"1513_CR6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJM196212272672608","volume":"267","author":"AT Ladd","year":"1962","unstructured":"Ladd AT (1962) Procainamide-induced lupus erythematosus. N Engl J Med 267:1357\u20131358","journal-title":"N Engl J Med"},{"key":"1513_CR7","first-page":"25","volume":"23","author":"MM Hargraves","year":"1948","unstructured":"Hargraves MM, Richmond H, Morton R (1948) Presentation of two bone marrow elements: the tart cell and the LE cell. Proc Staff Meet Mayo Clin 23:25","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"1513_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","volume":"43","author":"FW Miller","year":"2000","unstructured":"Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA (2000) Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 43:243\u2013249","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1513_CR9","first-page":"1","volume":"51","author":"R Yung","year":"2002","unstructured":"Yung R, Richardson B (2002) Drug-induced rheumatic syndromes. Bull Rheum Dis 51(4):1\u20134","journal-title":"Bull Rheum Dis"},{"key":"1513_CR10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0889-857X(21)00226-X","volume":"20","author":"RL Yung","year":"1994","unstructured":"Yung RL, Richardson BC (1994) Drug-induced lupus. Rheumatic Dis Clin N Amer 20:61\u201386","journal-title":"Rheumatic Dis Clin N Amer"},{"key":"1513_CR11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annepidem.2005.08.001","volume":"15","author":"AJ DeRoos","year":"2005","unstructured":"DeRoos AJ, Cooper GS, Alavanja MC, Sandler DP (2005) Rheumatoid arthritis among women in the agricultural health study: risk associated with farming activities and exposures. Ann Epidemiol 15:762\u2013770","journal-title":"Ann Epidemiol"},{"key":"1513_CR12","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1002\/art.22880","volume":"56","author":"LS Gold","year":"2007","unstructured":"Gold LS, Ward MH, Dosemeci M, DeRoos AJ (2007) Systemic autoimmune disease mortality and occupational exposures. Arthritis Rheum 56:3189\u20133201","journal-title":"Arthritis Rheum"},{"key":"1513_CR13","doi-asserted-by":"crossref","unstructured":"Sawalha AH, Richardson BC (2007) The environment in the pathogenesis of systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS, eds. Systemic lupus erythematosus: a companion to rheumatology. Mosby\/Elsevier, pp 64-73","DOI":"10.1016\/B978-0-323-04434-9.50012-9"},{"key":"1513_CR14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ncprheum0435","volume":"3","author":"M Gourley","year":"2007","unstructured":"Gourley M, Miller FW (2007) Mechanisms of disease: environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol 3:172\u2013179","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1513_CR15","first-page":"183","volume":"14","author":"L Lossaso","year":"2001","unstructured":"Lossaso L, Rapport LJ, Axelrod BN (2001) Neuropsycholgical symptoms associated with low-level exposure to solvent and (Meth)acrylates among nail technicians. Neuropsych Neuropsych Behav Neurol 14:183\u2013189","journal-title":"Neuropsych Neuropsych Behav Neurol"},{"key":"1513_CR16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/03009749409099278","volume":"23","author":"I Lundberg","year":"2004","unstructured":"Lundberg I, Alfredsson L, Plato N, Sverdrup B, Klareskog L, Kleinau S (2004) Occupation, occupational exposure to chemicals and rheumatological disease: a register-based cohort study. Scand J Rheumatol 23:305\u2013310","journal-title":"Scand J Rheumatol"},{"key":"1513_CR17","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M DeBandt","year":"2004","unstructured":"DeBandt M, Sibilia J, Le Lo\u00eb\u00ebt X, Poruzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation (2004) Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545\u2013R551","journal-title":"Arthritis Res Ther"},{"key":"1513_CR18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0961203306070000","volume":"15","author":"S Vasoo","year":"2006","unstructured":"Vasoo S (2006) Drug-induced lupus: an update. Lupus 15:757\u2013761","journal-title":"Lupus"},{"key":"1513_CR19","first-page":"45","volume":"10","author":"JM Murry","year":"1988","unstructured":"Murry JM, Butler JR (1988) Neuropsychological dysfunctioning associated with the dental office environment. Intl J Biosoc Res 10:45\u201368","journal-title":"Intl J Biosoc Res"},{"key":"1513_CR20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1302\/0301-620X.78B4.0780546","volume":"78B","author":"FS Haddad","year":"1996","unstructured":"Haddad FS, Cobb AG, Bentley G, Levell NJ, Dowd PM (1996) Hypersensitivity in aseptic loosening of total hip replacements. J Bone Joint Surg 78B:546\u2013549","journal-title":"J Bone Joint Surg"},{"key":"1513_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/17453677608998965","volume":"47","author":"L Linder","year":"1976","unstructured":"Linder L (1976) Tissue reaction to methyl methacrylate monomer. Acta Orthopaed Scand 47:3\u201310","journal-title":"Acta Orthopaed Scand"},{"key":"1513_CR22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0196-0644(88)80304-4","volume":"17","author":"JL Potter","year":"1988","unstructured":"Potter JL, Krill CE Jr, Neal D, Kofron WG (1988) Methemoglobinemia due to ingestion of N, N-dimethyl-p-toluidine, a component used in the fabrication of artificial nails. Ann Emerg Med 17:161\u2013163","journal-title":"Ann Emerg Med"},{"key":"1513_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0142-9612(96)00121-4","volume":"18","author":"S Stea","year":"1997","unstructured":"Stea S, Granchi D, Zolezzi C, Ciapetti G, Visentin M, Cavedagna D, Pizzoferrato A (1997) High-performance liquid chromatography assay of N, N-dimethyl-\u2009=\u2009p-toluidine released from bone cements: evidence for toxicity. Biomaterials 18:243\u2013246","journal-title":"Biomaterials"},{"key":"1513_CR24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/em.2850210406","volume":"21","author":"M Taningher","year":"1993","unstructured":"Taningher M, Pasquini R, Bonatti S (1993) Genotoxicity analysis of N, N-dimethylaniline and N, N-dimethyl-p-toluidine. Environ Mol Mutagen 21:349\u2013356","journal-title":"Environ Mol Mutagen"},{"key":"1513_CR25","unstructured":"Tesk JA, Antonucci JM, Eichmiller FC, Kelly JR, Rupp NW, Waterstrat RW, Fraker AC, Chow LC, George LA, Stanbury JW, Parry EE (1993) Dental materials. In: Kroschwitz JI, Howe-Grant M (eds) Kirk-Othmer encyclopedia of chemical technology, 4th edn. New York: Wiley 7:946-1022"},{"key":"1513_CR26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0536.1990.tb01533.x","volume":"22","author":"A Tosti","year":"1990","unstructured":"Tosti A, Bardazzi F, Piancastelli E, Brasile GP (1990) Contact stomatitis due to N, N-dimethyl-para-toluidine. Contact Dermat 22:113","journal-title":"Contact Dermat"},{"key":"1513_CR27","first-page":"118","volume":"13S","author":"RL Rubin","year":"1987","unstructured":"Rubin RL, Waqa S (1987) Antihistone antibodies in systemic lupus erythematosus. J Rheumatol 13S:118\u2013126","journal-title":"J Rheumatol"},{"key":"1513_CR28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.1981.00510060080016","volume":"38","author":"E Niakan","year":"1981","unstructured":"Niakan E, Bertorini TE, Acchiardo SR, Werner MF (1981) Procainamide-induced myasthenia-like weakness in a patient with peripheral neuropathy. Arch Neurol 38:378\u2013379","journal-title":"Arch Neurol"},{"key":"1513_CR29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijcard.2005.06.016","volume":"110","author":"SF Pasha","year":"2006","unstructured":"Pasha SF, Pruthi RK (2006) Procainamide-induced pure red cell aplasia. Intl J Cardiol 110:125\u2013126","journal-title":"Intl J Cardiol"},{"key":"1513_CR30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1172\/JCI117305","volume":"94","author":"RW Burlingame","year":"1994","unstructured":"Burlingame RW, Boey ML, Starkebaum G, Rubin RL (1994) The central role of chromatin in the autoimmune response to histones and DNA in systemic lupus erythematosus. J Clin Invest 94:184\u2013192","journal-title":"J Clin Invest"},{"key":"1513_CR31","first-page":"905","volume":"9","author":"DW Hein","year":"2000","unstructured":"Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidem Biomark Prevent 9:905\u2013910","journal-title":"Cancer Epidem Biomark Prevent"},{"key":"1513_CR32","first-page":"299","volume":"2","author":"N Rothman","year":"1993","unstructured":"Rothman N, Stewart WF, Caporaso NE, Hayes RB (1993) Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidem Biomark Preven 2:299\u2013303","journal-title":"Cancer Epidem Biomark Preven"},{"key":"1513_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1373\/clinchem.2005.061325","volume":"52","author":"Y Zhu","year":"2006","unstructured":"Zhu Y, Hein DW, Doll MA, Reynolds KK, Abudu N, Valdes R Jr, Linder MW (2006) Simultaneous determination of 7 N-acetyltransferase-2 sequence variations by allele-specific primer extension assay. Clin Chem 52:1\u20137","journal-title":"Clin Chem"},{"key":"1513_CR34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1158\/1055-9965.1543.13.9","volume":"13","author":"AC Deitz","year":"2004","unstructured":"Deitz AC, Rothman N, Rebbeck TR, Hayes RB, Chow W-H, Zheng W, Hein DW, Garcia-Closas M (2004) Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2(NAT2), smoking, and bladder cancer. Cancer Epidem Biomark Preven 13:1543\u20131546","journal-title":"Cancer Epidem Biomark Preven"},{"key":"1513_CR35","first-page":"2492","volume":"29","author":"E Tanaka","year":"2002","unstructured":"Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29:2492\u20132499","journal-title":"J Rheumatol"},{"key":"1513_CR36","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0002-9343(83)90885-9","volume":"75","author":"MM Reidenberg","year":"1983","unstructured":"Reidenberg MM (1983) Aromatic amines and the pathogenesis of lupus erythematosus. Amer J Med 75:1037\u20131042","journal-title":"Amer J Med"},{"key":"1513_CR37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.1977.03280090052024","volume":"238","author":"GC Stringer","year":"1977","unstructured":"Stringer GC, Hunter SW, Bonnabeau RC Jr (1977) Hypersensitivity pneumonitis following prolonged inhalation of hair spray. Thesaurosis JAMA 238:888\u2013889","journal-title":"Thesaurosis. JAMA"},{"key":"1513_CR38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-007-0728-5","volume":"26","author":"M Benucci","year":"2007","unstructured":"Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M (2007) Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNF alpha-blocking agents in rheumatoid arthritis. Clin Rheumatol 26:91\u201395","journal-title":"Clin Rheumatol"},{"key":"1513_CR39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajim.1098","volume":"40","author":"BK Aryal","year":"2001","unstructured":"Aryal BK, Khuder SA, Schaum A (2001) Meta-analysis of systemic sclerosis and exposure to solvents. Amer J Indust Med 40:271\u2013274","journal-title":"Amer J Indust Med"},{"key":"1513_CR40","first-page":"97","volume":"34","author":"A Kettaneh","year":"2007","unstructured":"Kettaneh A, Al Moufti O, Tiev KP, Chayet C, Toledano C, Fabre B, Fardet L, Cabane J (2007) Occupational exposure to solvents and gender related risk of systemic sclerosis: a meta-analysis of case-control studies. J Rheumatol 34:97\u2013103","journal-title":"J Rheumatol"},{"key":"1513_CR41","first-page":"2395","volume":"31","author":"A Maitre","year":"2004","unstructured":"Maitre A, Houra M, Bonneterre V, Arslan MT, Bergeret A, de Gaudemaris R, Carpentier P (2004) Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 31:2395\u20132401","journal-title":"J Rheumatol"},{"key":"1513_CR42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0190-9622(88)70046-8","volume":"18","author":"RG Phelps","year":"1988","unstructured":"Phelps RG, Fleishmajer R (1988) Clinical, pathologic, and immunopathologic manifestations of the toxic oil syndrome: analysis of fourteen cases. J Amer Acad Dermatol 18:313\u2013324","journal-title":"J Amer Acad Dermatol"},{"key":"1513_CR43","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.1972.03210120049014","volume":"222","author":"GJ Beirne","year":"1972","unstructured":"Beirne GJ (1972) Goodpasture\u2019s syndrome and exposure to solvents. JAMA 222:1555","journal-title":"JAMA"},{"key":"1513_CR44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/taap.1995.1179","volume":"134","author":"MF Khan","year":"1995","unstructured":"Khan MF, Kaphalia BS, Prabhakar BS, Kanz MF, Ansari GA (1995) Tricholorethene-induced autoimmune response in female MRL+\/+ mice. Toxicol Appl Pharmacol 134:155\u2013160","journal-title":"Toxicol Appl Pharmacol"},{"key":"1513_CR45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/bmj.281.6236.353","volume":"281","author":"RF Bing","year":"1980","unstructured":"Bing RF, Russell GI, Thurston H, Swales JO (1980) Hydralazine in hypertension: is there a safe dose? Brit Med J 281:353\u2013354","journal-title":"Brit Med J"},{"key":"1513_CR46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/bmj.281.6235.273-a","volume":"281","author":"SJ Harland","year":"1980","unstructured":"Harland SJ, Facchini V, Timbrell JA (1980) Hydralazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype. Brit Med J 281:273\u2013274","journal-title":"Brit Med J"},{"key":"1513_CR47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.0954-6820.1975.tb19578.x","volume":"198","author":"NC Henningsen","year":"1978","unstructured":"Henningsen NC, Cederberg A, Hanson A, Johansson BW (1978) Effects of long-term treatment with procainamide. Acta Med Scand 198:475\u2013482","journal-title":"Acta Med Scand"},{"key":"1513_CR48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0002-9343(73)90084-3","volume":"54","author":"HM Perry Jr","year":"1973","unstructured":"Perry HM Jr (1973) Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Amer J Med 54:58\u201371","journal-title":"Amer J Med"},{"key":"1513_CR49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2165\/00003088-198106020-00003","volume":"6","author":"JP Uetrecht","year":"1981","unstructured":"Uetrecht JP, Woosley RL (1981) Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 6:118\u2013134","journal-title":"Clin Pharmacokinet"},{"key":"1513_CR50","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJM197805252982101","volume":"298","author":"RL Woosley","year":"1978","unstructured":"Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA (1978) Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298:1157\u20131159","journal-title":"N Engl J Med"},{"key":"1513_CR51","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/tx980001t","volume":"12","author":"C Goebel","year":"1999","unstructured":"Goebel C, Vogel C, Wulferink M, Mittmann S, Sachs B, Scharaa S, Abel J, Degen G, Uetrecht J, Gleichmann E (1999) Procainamide, a drug causing lupus, induces prostaglanding H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages. Chem Res Toxicol 12:488\u2013500","journal-title":"Chem Res Toxicol"},{"key":"1513_CR52","first-page":"239","volume-title":"Autoimmunity and toxicology: immune disregulation induced by drugs and chemicals","author":"DW Hein","year":"2002","unstructured":"Hein DW, Weber WW (2002) Metabolism of procainamide, hydralazine and isoniazid in relation to autoimmune reactions. In: Kammuller ME, Bloksma N, Seinen W (eds) Autoimmunity and toxicology: immune disregulation induced by drugs and chemicals. Elsevier Science Publishers, New York, pp 239\u2013265"},{"key":"1513_CR53","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI114020","volume":"83","author":"RL Rubin","year":"1989","unstructured":"Rubin RL, Curnutte JT (1989) Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro. J Clin Invest 83:1336\u20131343","journal-title":"J Clin Invest"},{"key":"1513_CR54","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(25)20618-8","volume":"232","author":"JP Uetrecht","year":"1985","unstructured":"Uetrecht JP (1985) Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 232:420\u2013425","journal-title":"J Pharmacol Exp Ther"},{"key":"1513_CR55","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/00007611-200111000-00017","volume":"94","author":"JD Carter","year":"2001","unstructured":"Carter JD, Valeriano-Marcet J, Kanik KS, Vasey FB (2001) Antinuclear antibody-negative, drug-induced lupus caused by lisinopril. South Med J 94:1122\u20131123","journal-title":"South Med J"},{"key":"1513_CR56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780260108","volume":"26","author":"BM Rothschild","year":"1983","unstructured":"Rothschild BM, Verrier Jones J, Chesney C, Pifer DD, Thompson LD, James KK, Badger H (1983) Relationship of clinical findings in systemic lupus erythematosus to seroreactivity. Arthritis Rheum 26:45\u201351","journal-title":"Arthritis Rheum"},{"key":"1513_CR57","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.11033","volume":"48","author":"E Carlson","year":"2003","unstructured":"Carlson E, Rothfield N (2003) Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 48:1165\u20131166","journal-title":"Arthritis Rheum"},{"key":"1513_CR58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.berh.2004.05.006","volume":"18","author":"NJ Olson","year":"2004","unstructured":"Olson NJ (2004) Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 18:677\u2013688","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1513_CR59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/03009740701218717","volume":"36","author":"A Braun","year":"2007","unstructured":"Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, Andrassy K (2007) Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 36:291\u2013298","journal-title":"Scand J Rheumatol"},{"key":"1513_CR60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00351164","volume":"23","author":"RW Burlingame","year":"1996","unstructured":"Burlingame RW, Rubin RL (1996) Autoantibody to the nucleosome subunit (H2a-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions. Mol Biol Rep 23:159\u2013166","journal-title":"Mol Biol Rep"},{"key":"1513_CR61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molcel.2006.06.017","volume":"23","author":"AL Clayton","year":"2006","unstructured":"Clayton AL, Hazzalin CA, Mahadevan LC (2006) Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 23:289\u2013296","journal-title":"Mol Cell"},{"key":"1513_CR62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhep.2006.11.007","volume":"46","author":"AM Elsharkawy","year":"2007","unstructured":"Elsharkawy AM (2007) Todralazine hepatotoxicity: a sting in the histone tail. J Hepatol 46:189\u2013192","journal-title":"J Hepatol"},{"key":"1513_CR63","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/art.22646","volume":"56","author":"JW Dieker","year":"2007","unstructured":"Dieker JW, Fransen JH, van Bavel CC, Briand J-P, Jacobs CW, Muller S, Berden JH, van der Vlag J (2007) Aptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 56:1921\u20131933","journal-title":"Arthritis Rheum"},{"key":"1513_CR64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00296-004-0494-5","volume":"26","author":"R Callskan","year":"2005","unstructured":"Callskan R, Masatlioglu S, Aslan M, Altun M, Saribas S, Ergin S, Uckan E, Koksal V, Oz V, Altas K, Fresko I, Kocazeybek B (2005) The relationship between arthritis and human parvovirus B19 infection. Rheumatol Intl 26:7\u201311","journal-title":"Rheumatol Intl"},{"key":"1513_CR65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1172\/JCI116576","volume":"92","author":"J Quddus","year":"1993","unstructured":"Quddus J, Johnson KJ, Galvalchin J, Amento EP, Chrisp CE, Yung RL, Richardson BC (1993) Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-Azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92:38\u201353","journal-title":"J Clin Invest"},{"key":"1513_CR66","first-page":"1083","volume":"24","author":"JT Merrill","year":"1997","unstructured":"Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey A-B (1997) High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 24:1083\u20131088","journal-title":"J Rheumatol"},{"key":"1513_CR67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/pmj.79.928.81","volume":"79","author":"GR Hughes","year":"2003","unstructured":"Hughes GR (2003) Migraine, memory loss, and \u2018multiple sclerosis\u2019. Neurological features of the antiphospholipid (Hughes\u2019) syndrome. Postgrad Med J 79:81\u201383","journal-title":"Postgrad Med J"},{"key":"1513_CR68","first-page":"282","volume-title":"Casarett and Doull\u2019s toxicology","author":"JH Dean","year":"1991","unstructured":"Dean JH, Murray MJ (1991) Toxic responses to the immune system. In: Amdur M, Doull J, Klaassen CD (eds) Casarett and Doull\u2019s toxicology. Pergamon Press, New York, pp 282\u2013333"},{"key":"1513_CR69","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/archinte.168.10.1030","volume":"168","author":"RL Kravitz","year":"2008","unstructured":"Kravitz RL, Duan N, White RH (2008) N-of-1 trials of expensive biological therapies. Arch Intern Med 168:1028\u20131033","journal-title":"Arch Intern Med"},{"key":"1513_CR70","unstructured":"Gladman D, Chalmers A, Urowitz MB (1997) Serologically negative systemic lupus erythematosus. XIV International Congress of Rheumatology, San Francisco. 1997:186"},{"key":"1513_CR71","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/rheumatology\/keq018","volume":"49","author":"J Alshekaili","year":"2010","unstructured":"Alshekaili J, Li C, Cook MC (2010) Heterophile interference accounts for method-specific dsDNA antibodies in patients receiving anti-TNF treatment. Rheumatology 49:891\u2013897","journal-title":"Rheumatology"},{"key":"1513_CR72","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.090100","volume":"36","author":"M Laroche","year":"2009","unstructured":"Laroche M, Brouchet A, Mazi\u00e8res B (2009) Multifocal bone infarcts and buprenorphine: association or coincidence? J Rheumatol 36:2369\u20132370","journal-title":"J Rheumatol"},{"key":"1513_CR73","doi-asserted-by":"crossref","unstructured":"Slimani S, Ben Ammar A, Ladjouze-Rezig A (2010) Connective tissue diseases after heavy exposure to silica: a report of nine cases in stonemasons. Clin Rheumatol 28. doi: 10.1007\/s10067-009-1371-0","DOI":"10.1007\/s10067-009-1371-0"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1513-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1513-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1513-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:19:22Z","timestamp":1740176362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1513-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,11]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1513-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,11]]}}}